Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216560 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of 7MW4911 in GI Cancer
A Phase 1 study of GI Cancers, sponsored by Mabwell (Shanghai) Bioscience Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT07216560 is a Phase 1 study of GI Cancers that is actively recruiting participants, run by Mabwell (Shanghai) Bioscience Co.. The registered enrollment target is 200 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07216560, a Phase 1 study of GI Cancers, is actively recruiting participants, sponsored by Mabwell (Shanghai) Bioscience Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Conditions Studied
Interventions
- DRUG 7MW4911
Study Locations (4)
Florida
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
New York
- START - Long Island City
Utah
- START Moutain Region - West Valley City
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216560
The ClinicalTrials.gov registry entry for NCT07216560 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mabwell (Shanghai) Bioscience Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GI Cancers appearing as the primary indexed condition, and to 1 intervention - of which 7MW4911 is the first listed.
NCT07216560 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, New York, Utah.
Frequently Asked Questions
What is clinical trial NCT07216560 about?
NCT07216560 is a clinical study titled "First-in-human Study of 7MW4911 in GI Cancer". This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
What is the current status of trial NCT07216560?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2026-01-13. Estimated completion is 2028-12.
What conditions does trial NCT07216560 study?
This clinical trial studies the following conditions: GI Cancers.
What interventions are being tested in trial NCT07216560?
The interventions under investigation include: 7MW4911 (DRUG).
Who is sponsoring clinical trial NCT07216560?
This trial is sponsored by Mabwell (Shanghai) Bioscience Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216560 being conducted?
This trial has 4 study locations across Florida, New York, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.